AMG 986
Phase 2
AmgenAMG 986 is one of 35 therapeutic programs targeting Celiac Disease. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
52 competitors in Celiac Disease
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
VIOKACE
DDigestive Care, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ferinject
VVifor Pharma
Approved
Iron
WWatson Pharmaceuticals
Approved
Zocor
OOrganon and Co
Phase 3
Opzelura
PfizerPhase 2
Entyvio
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for AMG 986. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company